Professor
Tim Hughes
FAA FAHMS
Timothy Hughes has made key contributions towards the development and refinement of kinase inhibitor therapy for cancer, through his pioneering work in chronic myeloid leukaemia (CML). He was a leader on many of the key clinical trials that underpinned the transformation of CML from a fatal disease to a treatable chronic disease. Hughes demonstrated and championed the key role of molecular monitoring to optimise response in CML. He pioneered the concept of treatment-free remission as a pathway to cure in CML. This has heralded an exciting new era in cancer therapy where molecularly-defined targets are identified and specifically inhibited.
Fields of research
32 BIOMEDICAL AND CLINICAL SCIENCES-
3201
CARDIOVASCULAR MEDICINE AND HAEMATOLOGY
- 320102 Haematology
-
3211
ONCOLOGY AND CARCINOGENESIS
- 321104 Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
For full list of research codes, please visit the ARC Website .
Expertise type
- Biomarkers
- Cancer Biology
- Medical Sciences
- Genomics
- Cancer
- Haematology
Please contact fellowship@science.org.au to request any updates to the data.